Thermo Fisher Scientific significantly exceeded Wall Street's second-quarter 2026 expectations, reporting revenue of $11.99 billion, a 10% increase year-over-year, and adjusted earnings per share of $6.03. This performance beat the consensus estimates of $11.70 billion in revenue and $5.71 in adjusted EPS. The company's adjusted operating margin expanded by 90 basis points to 22.8% from 21.9% in the prior year, indicating efficient conversion of higher revenue into profits.
The life sciences tools giant raised its full-year 2026 adjusted EPS guidance to a range of $24.93 to $25.33, up from the previous forecast of $24.64 to $25.12. This increase reflects strong operational performance in Q2 and an improved outlook for the second half of the year, alongside the anticipated impact of the divestiture of its microbiology business. The company also raised its revenue guidance to a new range of $47.4 billion to $48.1 billion, representing 6%-8% reported revenue growth over 2025, and increased its expectation for full-year organic revenue growth to about 4%, aiming for the upper end of its 3%-4% guidance range.
Customer activity strengthened across all end markets, particularly in pharma and biotech, which saw mid-single-digit growth led by bioproduction and clinical research businesses. Academic and government segments grew low single digits, while industrial and applied segments also achieved mid-single-digit growth. This broad-based improvement signals a thawing of the post-pandemic research spending slump and an end to the inventory correction that affected the life-sciences tools sector. The company also actively managed its portfolio, divesting its microbiology business and repurchasing $1 billion of its shares in the second quarter.
Following the strong results and raised guidance, Thermo Fisher's shares surged approximately 10% in premarket trading to $575.17, up from a previous close of $526.46. While the market reacted positively, analysts noted that the stock's forward price-to-earnings ratio might now price in faster growth than the sector can sustainably deliver, especially if demand from academic and government sectors in China remains muted, as cautioned by CEO Marc Casper. Finance chief Jim Meyer confirmed that the outlook for these segments was not changed, suggesting the recovery is not entirely uniform across all markets.
